Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

NCT04191135 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

462

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Olaparib
DRUG: Carboplatin
DRUG: Gemcitabine

Sponsor

Merck Sharp & Dohme LLC